The Adiponectin Paradox for All-Cause and Cardiovascular Mortality

Claudia Menzaghi1 and Vincenzo Trischitta1,2

Basic science studies have shown beneficial effects of adiponectin on glucose homeostasis, chronic low-grade inflammation, apoptosis, oxidative stress, and atherosclerotic processes, so this molecule usually has been considered a salutary adipokine. It was therefore quite unexpected that large prospective human studies suggested that adiponectin is simply a marker of glucose homeostasis, with no direct favorable effect on the risk of type 2 diabetes and cardiovascular disease. But even more unforeseen were data addressing the role of adiponectin on the risk of death. In fact, a positive, rather than the expected negative, relationship was reported between adiponectin and mortality rate across many clinical conditions, comprising diabetes. The biology underlying this paradox is unknown. Several explanations have been proposed, including adiponectin resistance and the confounding role of natriuretic peptides. In addition, preliminary genetic evidence speaks in favor of a direct role of adiponectin in increasing the risk of death. However, none of these hypotheses are based on robust data, so further efforts are needed to unravel the elusive role of adiponectin on cardiometabolic health and, most important, its paradoxical association with mortality rate.

Diabetes is one of the most challenging global health problems, affecting an estimated 415 million people worldwide (1). The increased mortality rate observed in patients with diabetes (2), especially those with type 2 diabetes, contributes substantially to the heavy burden that the disease exerts on patients and their relatives and the entire society, with an annual economic cost that in the U.S. alone approximates $100 billion (1).

Discovering novel biomarkers able to predict the risk of mortality in patients with diabetes and furthering the understanding of their mechanisms may help in tackling such a tremendous burden.

Notably, there are no diabetes-specific death-predicting markers. This indicates that though being possibly exacerbated and certainly more prevalent in individuals with versus without diabetes, the mechanisms underlying mortality rate are not different across the two groups. Thus, when addressing the architecture of high mortality risk associated with diabetes, one should really look at molecules, pathways, and pathogenic scenarios that are shared by the general population and presumably several other clinical conditions.

It is now established that processes related to intermediate metabolism, low-grade inflammation, and atherosclerosis are instrumental in shaping the risk of mortality. So, it is not surprising that several adipokines controlling most of the above-mentioned processes do influence mortality rate (3). Among these is adiponectin, a 244 amino acid protein abundantly present in serum (3).

The major aim of this article is to acquaint the readers with the counterintuitive and therefore unexpected relationship between circulating adiponectin levels and mortality rate that has emerged in recent years. In fact, it will be reported and discussed how, despite the well-recognized role of adiponectin as insulin-sensitizing, anti-inflammatory, and cardioprotective factor in cellular and animal models, a direct association between serum adiponectin and mortality rate has been repeatedly and almost uniformly reported within several clinical settings, including diabetes. Although the intimate mechanisms of such paradox are not yet known, some hypotheses, based on intriguing preliminary evidences, will be offered. Finally, we will propose a frame that may help in designing and conducting future studies aimed at better understanding the adiponectin paradoxical association with increased mortality risk.
BASIC SCIENCE EVIDENCE OF ADIPONECTIN’S BENEFICIAL ROLE ON CARDIOMETABOLIC TRAITS

After posttranslational modifications, adiponectin circulates in trimeric, hexameric, and multimeric high–molecular weight (HMW) isoforms, each activating different signal transduction pathways and possibly leading to distinct biological functions (3). Levels of all circulating adiponectin isoforms are 30–80% heritable, suggesting that they are, at least partly, under genetic control. The ADIPOQ gene in chromosome 3q27 and several other loci has been reported by genome-wide association studies (GWAS) to associate with serum adiponectin (4–6).

Adiponectin acts through at least two receptors, AdipoR1 and AdipoR2, which show different binding affinity for globular and full-length adiponectin. AdipoR1 is ubiquitously expressed, whereas AdipoR2 is mostly expressed in white adipose tissue and liver (7). Adiponectin through adenosine 5’-monophosphate–activated protein kinase or peroxisome proliferator–activated receptor α activation inhibits gluconeogenesis and stimulates glucose uptake (7).

Besides the effects on glucose metabolism, adiponectin has been also indicated as a cardioprotective molecule by several in vitro studies (8–10). In fact, adiponectin plays a beneficial role on low-grade inflammation by suppressing the expression of IL-8 in tumor necrosis factor α (TNFα)-stimulated human aortic endothelial cells (8). It also suppresses the expression of TNFα and monocyte chemo-attractant protein 1 in several cell types (including human circulating monocyte-derived macrophages, stromal vascular fraction cells from human subcutaneous fat pads, and murine alveolar macrophages [9]) and of vascular cell adhesion molecule 1 and TNFα in atherosclerotic lesions of apoE-deficient mice (10). Conversely, in human monocyte-derived macrophages, adiponectin enhances the expression of anti-inflammatory cytokine IL-10 (11). In a mice model with targeted activation of caspase-8, adiponectin exerts antipapoptotic effects in primary neonatal ventricular cardiac myocytes (12), whereas in db/db mouse aortic endothelial cells it mitigates oxidative stress by increasing nitric oxide bioavailability through adenosine 5’-monophosphate–activated protein kinase and protein kinase A (13). In addition, adiponectin exerts a protective effect on glomerular podocytes by significantly restoring their foot processes in adiponectin knockout mice (14). Finally, through the marked downregulation of scavenger receptor A, adiponectin suppresses the transformation of human monocyte-derived macrophages into foam cells, thus inhibiting the development of atherosclerotic plaques (15).

Although addressing different cell types from different species as well as different pathways possibly involved in atherosclerosis, these studies draw a picture indicating adiponectin as a beneficial molecule for the vasculature, the heart, and, in general, cardiometabolic health.

In the specific context of the adiponectin cardioprotective effect, a significant role seems to be played by T-cadherin identified in C2C12 myoblasts and rodent skeletal muscle as a specific cell membrane binding protein for HMW adiponectin (16). Notably, T-cadherin, which is encoded by the CDH13 gene, is highly expressed throughout the vasculature, including endothelial cells, smooth muscle cells, and pericytes (17). The role of T-cadherin is critical for cardiovascular protection in several mice models (18,19), with binding to adiponectin mitigating stress-induced cardiac remodeling (18), mediating revascularization after hind limb remodeling (19), and protecting against neointimal and atherosclerotic plaque formation (20).

RELATIONSHIP BETWEEN ADIPONECTIN AND CARDIOMETABOLIC TRAITS

On the basis of the above-reported properties unraveled by basic science studies, it would be conceivable to hypothesize that adiponectin exerts beneficial effects on metabolic and cardiovascular traits in human beings. In fact, in pioneering cross-sectional studies carried out in Pima Indians, circulating adiponectin levels correlated positively with both skeletal muscle (21) and liver (22) insulin sensitivity. In addition, in this same population, adiponectin was negatively correlated with fasting triglycerides and inflammatory markers (23). Along the same line is the observation that insulin-sensitizing agents increase adiponectin concentrations in humans (24). In addition, a prospective study has also shown that low plasma adiponectin concentration predicts the deterioration of insulin sensitivity over time (25).

Unfortunately, the observational design of all such studies could not address whether the reported associations were due to a positive effect of adiponectin on insulin sensitivity. In this regard, it must be considered that subjects with severe insulin resistance due to insulin receptor genetic abnormalities are characterized by increased circulating adiponectin levels (26); in addition, exogenous insulin administration reduces adiponectin levels in healthy individuals (27). Taken together, these two studies (26,27) suggest that insulin is able to decrease circulating adiponectin levels, and therefore it becomes not clear how to interpret the relationship between hypoadiponectinemia and common forms of insulin resistance and hyperinsulinemia reported by epidemiological observational studies (21,22,25,28).

Genetic studies may help cope with similar elusive interpretations on the relationship between a given intermediate trait and an outcome of interest. In fact, if genetic variants robustly affecting the trait are available, their association with the outcome is used to speak in favor of causality. This approach, named as Mendelian randomization (29), has been used to address the relationship between low adiponectin and insulin resistance, giving, unfortunately, ambiguous results (30,31). On one hand, it has been reported that a genetic score including variants in the ADIPOQ locus was strongly and directly associated with both high serum adiponectin levels and increased insulin sensitivity at euglycemic-hyperinsulineic glucose clamp, suggesting that adiponectin does increase insulin sensitivity (30). On the other hand, in a second larger study a genetic score also built on ADIPOQ variants showed no association with higher fasting...
| First author, year (ref.) | Study population | Subjects (n) | Deaths (n) | Adiponectin-mortality association |
|--------------------------|------------------|-------------|-----------|-----------------------------------|
| Efstathiou, 2005 (65)    | Ischemic stroke  | 160         | 85        | ↓                                 |
| Kistorp, 2005 (66)       | Chronic heart failure | 195       | 46        | ↑                                 |
| Pitz, 2006 (67)          | General population (78.6% with coronary artery disease) | 3,146     | 482       | ↑                                 |
| Cavusoglu, 2006 (68)     | General population | 325        | 33        | ↑                                 |
| Menon, 2006 (57)         | Chronic kidney disease | 820       | 323       | ↑                                 |
| George, 2006 (69)        | Chronic heart failure | 175       | 36        | ↑                                 |
| Wannamethee, 2007 (70)   | General population | 3,099      | 465       | ↑                                 |
|                          | Chronic heart failure | 830       | 217       | ↔                                 |
|                          | Chronic heart failure | 117       | 52        | ↔                                 |
| Laughlin, 2007 (71)      | Community dwelling | 1,361      | 925       | ↑                                 |
| Tsutamoto, 2007 (43)     | Chronic heart failure | 449       | 47        | ↑ ←⇒ζ                            |
| Dekker, 2008 (72)        | General population (with no history of CVD) | 1,886      | 340       | ↔                                 |
|                          | General population (with history of CVD) | 433       | 164       | ↑                                 |
| Jorsal, 2008 (73)        | Type 1 diabetes (100% end-stage renal disease) | 373       | 98        | ↑                                 |
| Rao, 2008 (74)           | End-stage renal disease | 182       | 107       | ↓                                 |
| Ohashi, 2008 (75)        | Hemodialysis | 74          | 15        | ↑                                 |
| Lee, 2009 (76)           | Acute myocardial infarction | 397       | 28        | ↑                                 |
| Poehls, 2009 (44)        | General population | 3,075      | 679       | ↑                                 |
| Diepinger, 2009 (77)     | Periphery artery disease | 487       | 114       | ↑                                 |
| Drechsler, 2009 (78)     | Type 2 diabetes (100% hemodialysis) | 1,249     | 617       | ↔                                 |
| Mikkelsen, 2010 (79)     | Cardiac surgery | 836         | 40        | ↑                                 |
| Kizer, 2011 (80)         | Community dwelling | 840        | 176       | ↔ ↑^                             |
| Nagasawa, 2011 (81)      | Ischemic stroke | 548         | 39        | ↔                                 |
| Forsblom, 2011 (82)      | Type 1 diabetes | 2,034       | 173       | ↑                                 |
| Duggan, 2011 (83)©       | Breast cancer | 527         | 62        | ↔                                 |
| Waschki, 2011 (84)       | Chronic obstructive pulmonary disease | 169       | 26        | ↑                                 |
| Koch, 2011 (85)          | Critically ill | 170         | NR        | ↑                                 |
| Wannamethee, 2011 (86)¶ | General population | 2,879      | 667       | ↑                                 |
| Wilson, 2011 (87)        | Acute coronary syndrome | 3,931      | NR        | ↔                                 |
| Kizer, 2012 (88)#        | General population | 3,272      | 1,947     | ↔ ↑*                             |
|                          | CVD | 1,030       | 802       | ↑                                 |
|                          | Chronic heart failure or atrial fibrillation | 383       | 337       | ↑                                 |
| Beatty, 2012 (46)        | Ischemic heart disease | 981        | 375       | ↑                                 |
| Lindberg, 2012 (89)      | STEMI | 735        | 99        | ↑                                 |
| Abdallah, 2012 (90)      | Hemodialysis | 133        | 36        | ↑                                 |
| Persson, 2012 (91)       | Carotid endarterectomy | 292        | 52        | ↑                                 |
| Singer, 2012 (92)        | Type 2 diabetes | 609         | 92        | ↑                                 |
| Markaki, 2012 (93)       | Hemodialysis and peritoneal dialysis | 74        | 18        | ↑                                 |
| Yoon, 2012 (94)¶         | General population (smokers) | 4,686      | 438       | ↔                                 |
| Alam, 2013 (45)          | Kidney transplant | 952        | 122       | ↑                                 |
| Park, 2013 (95)          | End-stage renal disease | 131       | 22        | ↔                                 |
| Lindberg, 2013 (96)      | General population | 5,624      | 801       | ↑                                 |
| Hascoet, 2013 (97)¶      | General population (52% with coronary artery disease) | 1,497      | 193       | ↑                                 |
| Spoto, 2013 (98)         | Hemodialysis | 231         | 165       | ↓                                 |
| Uetani, 2014 (60)§       | Community dwelling | 2,020      | 84        | ↑                                 |
| Menzaghi, 2014 (50)#     | Type 2 diabetes (100% coronary artery disease) | 359       | 81        | ↑                                 |
| Szabó, 2014 (99)         | Chronic heart failure | 111        | 31        | ↑                                 |

*Continued on p. 15*
insulin (31), a proxy of insulin resistance, thus questioning a direct beneficial role of adiponectin on insulin sensitivity.

Prospective studies are available on the relationship between circulating adiponectin levels and incident type 2 diabetes, the most relevant outcome of insulin resistance. Although meta-analyses of these reports clearly indicate that high adiponectin levels do predict a reduced risk of type 2 diabetes (31,32), a large Mendelian randomization study carried out by using an ADIPOQ genetic risk score in more than 250,000 individuals, adiponectin-concentrations do not predict future cardiovascular events (35–38). In a Mendelian randomization study carried out in more than 250,000 individuals, adiponectin-increasing alleles were not associated with reduced risk of coronary heart disease (39), thus reinforcing the idea that adiponectin does not play a role in shaping cardiovascular risk. This again is an unexpected finding, given the favorable effects of adiponectin on lipid metabolism, chronic low-grade inflammation, endothelial function, and several aspects of atherosclerotic processes reported by studies in cellular and animal models (3,7–13,15,18–20). Also, in this case the large study sample size (39) makes the possibility of a false-negative result unlikely.

**PARADOXICAL ASSOCIATION OF ADIPONECTIN ON MORTALITY RATE**

Circulating adiponectin, both total and HMW adiponectin, has been reported to be positively associated with mortality rate across several clinical sets in the vast majority of available investigations, with only very few and small studies reporting the expected inverse relationship (Tables 1 and 2).

The first of such counterintuitive findings has been reported in patients with ischemic stroke and chronic heart failure (Tables 1 and 2). Similar independent associations have been later reported in asymptomatic elderly participants from the general population and in patients affected by several diseases, including coronary artery disease, peripheral arterial diseases, chronic kidney disease, and cancer. Similarly there are data obtained in patients with type
and type 2 diabetes in whom high adiponectin acts as an independent predictor of both all-cause and cardiovascular mortality.

Although, a meta-analysis of earlier studies (36) suggested that the paradoxical association between increased adiponectin and elevated mortality rate was only observed in the presence of cardiovascular disease (CVD), subsequent studies have clearly indicated that, no matter if total or HMW adiponectin was measured, it does occur across all clinical settings (Tables 1 and 2).

Despite in all prospective studies considered here, the paradoxical relationship between adiponectin and mortality risk was independent by several covariates (Tables 1 and 2); the intrinsic nature of study design cannot rule out if some factors that are strongly related to both adiponectin and mortality rate have nonetheless confounded it. Among these are several ongoing medications, especially in frail and elderly people, such as those with diabetes and CVD, who are often overtreated.

Given the established role of adiposity on both serum adiponectin levels (40) and mortality (41), BMI also is a candidate confounder/modifier on the counterintuitive association between adiponectin and mortality rate. Unfortunately, studies addressing this subject have shown

| First author, year (ref.) | Study population | Subjects (n) | Deaths (n) | Adiponectin-mortality association |
|---------------------------|------------------|-------------|------------|----------------------------------|
| Pilz, 2006 (67)           | General population (78.6% with coronary artery disease) | 3,146       | 427        | ↑                                |
| Cavusoglu, 2006 (68)      | General population | 325         | 20         | ↑                                |
| Menon, 2006 (57)          | Chronic kidney disease | 820         | 122        | ↑                                |
| Wannamethee, 2007 (70¶)   | General population¶| 3,099       | 166        | ↑                                |
|                         | CVD               | 830         | 113        | ↓                                |
|                         | Chronic heart failure | 117         | 30         | ↓                                |
| Laughlin, 2007 (71)       | Community dwelling | 1,361       | 441        | ↑                                |
| Dekker, 2008 (72)         | General population (no history of CVD) | 1,839       | 115        | ↔                                |
|                         | General population (history of CVD) | 417         | 88         | ↔                                |
| Maiolino, 2008 (110)      | CVD               | 712         | 45         | ↔                                |
| Lee, 2009 (76)            | Acute myocardial infarction | 397         | 20         | ↔                                |
| Poehls, 2009 (44)         | General population | 3,075       | 247        | ↑                                |
| Dieplinger, 2009 (77)     | Periphery artery disease | 487         | 69         | ↑                                |
| Forsblom, 2011 (82)       | Type 1 diabetes   | 2,034       | 173        | ↑                                |
| Nagasawa, 2011 (81)       | Ischemic stroke   | 548         | 15         | ↑                                |
| Wannamethee, 2011 (86)    | General population | 2,879       | 225        | ↑                                |
| Kizer, 2012 (88)#         | General population | 3,272       | 634        | ↔↑*( catastrophe)               |
|                         | CVD               | 1,030       | 375        | ↑                                |
|                         | Chronic heart failure or atrial fibrillation | 383         | 180        | ↑                                |
| Lindberg, 2012 (89)       | STEMI             | 735         | 50         | ↑                                |
| Yoon, 2012 (94¶)          | General population (smokers) | 4,686       | 106        | ↓                                |
| Persson, 2012 (91¶)       | Carotid endarterectomy | 292         | 27         | ↑                                |
| Spoto, 2013 (98)          | Hemodialysis      | 231         | 96         | ↓                                |
| Gardener, 2013 (111)      | General population | 2,091       | 410        | ↑                                |
| Hascoet, 2013 (97¶)       | General population (52% with coronary artery disease) | 1,497       | 117        | ↑                                |
| Menzaghi, 2014 (50)#      | Type 2 diabetes (100% with coronary artery disease) | 359         | 58         | ↑                                |
|                         | Type 2 diabetes© | 902         | 144        | ↔                                |
|                         | Type 2 diabetes¶ | 833         | 146        | ↑                                |
| Choi, 2015 (42)           | Community dwelling | 1,000       | 52         | ↑                                |
| Witberg, 2016 (104)       | General population | 3,263       | 63         | ↑                                |
| Liu, 2016 (59¶¶$)        | Type 2 diabetes $ | 950         | 220        | ↑                                |
| Bergmark, 2017 (48)       | Type 2 diabetes   | 5,213       | 184        | ↑                                |
| Ritsinger, 2017 (109)     | Acute myocardial infarction | 180         | 35         | ↔                                |

STEMI, ST-segment elevation myocardial infarction. ↑, ↔, and ↓, positive, neutral, and inverse correlation, respectively, between adiponectin (i.e., total when not otherwise specified) in fully adjusted models. ¶Only male. ©Only female. ¶¶HMW adiponectin. #Total and HMW adiponectin levels were measured, giving the same results. *No or positive association among individuals with adiponectin < or ≥12.4 mg/L, respectively. $Most of the patients comprised in this study had already been investigated in Menzaghi et al. (50).
discordant results (42–49). In fact, although some studies have reported a preferential adiponectin effect on mortality rate in specific BMI subgroups varying across studies (42–44), others have described no such effect modification in several clinical sets (45–47), including patients with type 2 diabetes (48,49).

We have recently reported that adiponectin levels seem to predict cardiovascular mortality in a sex-specific manner, with the paradoxical effect being observed in men but not women (50). A similar sexual dimorphism has been described also for the associations between adiponectin and other cardiovascular outcomes, including chronic kidney disease (51) and the progression of carotid intima-media thickness (52), suggesting this may be a phenomenon regarding several cardiovascular effects of adiponectin.

The biology underlying the counterintuitive association between high serum adiponectin concentration and increased mortality rate is not yet known, so only speculations can be offered in this article.

A reasonable possibility is that increasing adiponectin is a failing attempt to protect individuals with great risk of mortality. One of the reasons for such failing may be adiponectin resistance in metabolically active organs including the adipose tissue, skeletal muscle, liver, vasculature, and heart (53).

Another possible and certainly very intriguing explanation is that the adiponectin paradox is driven by the direct and strong correlation between adiponectin itself and natriuretic peptides (NPs), established risk factors of mortality rate (54). This hypothesis is based on studies showing that both atrial NP (ANP) and brain NP (BNP) enhance adiponectin production in human adipocytes (55) and that ANP infusion increases plasma adiponectin levels in humans (55). So, according to this hypothesis, NPs would be the real risk factors of mortality rate, with adiponectin being only a marker of increased NPs. However, studies in which the association between serum adiponectin and mortality rate was conditioned by NP circulating levels have given conflicting results. In detail, after taking into account NPs, the adiponectin paradox was no longer observed in some reports while remaining totally unaffected in others (Table 3). This makes it impossible to draw firm conclusions about the confounding role of NPs on the association between adiponectin and mortality rate.

Last, it could be hypothesized that reduced kidney function, an important cause of premature death (56), also acts as a confounder of the association between adiponectin and mortality (57). However, epidemiological studies do not support this hypothesis (57), with the paradoxical association between adiponectin and mortality rate being either independent (57) or synergic (49) to that of glomerular filtration rate.

By performing a pilot Mendelian randomization study, we have tried to provide our own contribution to unravel the biology underlying the adiponectin paradox (58). In 356 patients with diabetes and established coronary artery disease from the Gargano Heart Study (GHS) prospective design, a GWAS-derived single nucleotide polymorphism (SNP) in the ADIPOQ locus was firmly associated with adiponectin levels, as well as with cardiovascular mortality, thus pointing to a direct deleterious role of adiponectin in shaping the risk of death. Completely in contrast with our data (58), Liu et al. (59) found in 950 individuals from the Health Professionals Follow-Up Study (HPFS) that adiponectin-increasing alleles of 19 SNPs, considered together as a genetic risk score, were not associated with cardiovascular mortality in male patients with type 2 diabetes. Several differences across the two studies could explain the

| First author, year (ref.) | Subjects (n) | Deaths (n) | NPs | Adiponectin-mortality association | Adjustment for NPs |
|--------------------------|-------------|-----------|-----|---------------------------------|-------------------|
| Kistorp, 2005 (66)       | 195         | 46        | NT-proBNP | ↑↑                              | ↔                 |
| Pilz, 2006 (67)          | 3,146       | 482       | NT-proBNP | ↑↑                              | ↑↑                |
| George, 2006 (69)        | 175         | 36        | NT-proBNP | ↑↑                              | ↑↑                |
| Tsutamoto, 2007 (43)     | 449         | 47        | ANP, BNP, NT-proBNP | ↑↑                              | ↑                 |
| Dieplinger, 2009 (77)    | 487         | 114       | NT-proBNP | ↑↑                              | ↔                 |
| Drechsler, 2009 (78)     | 1,255       | 617       | NT-proBNP | ↔                               | ↔                 |
| Wannamethee, 2011 (86)*  | 2,879       | 667       | NT-proBNP | ↑↑                              | ↑                 |
| Wilson, 2011 (87)        | 3,931       | NR        | BNP   | ↔                               | ↔                 |
| Beatty, 2012 (46)        | 981         | 375       | NT-proBNP | ↑↑                              | ↑                 |
| Szabó, 2014 (99)         | 111         | 31        | ProANP | ↑↑                              | ↑                 |
| Lindberg, 2015 (102)     | 720         | 137       | ProANP | ↑↑                              | ↔                 |
| Witberg, 2016 (104)*     | 3,263       | 184       | NT-proBNP | ↑↑                              | ↑↑                |

NR, not reported; NT-proBNP, N-terminal proBNP. ↑↑ Positive association. ↑↓ Attenuated positive association. ↔ Neutral association. *In these studies, data on cardiovascular mortality are also available and report results similar to those on all-cause mortality.
divergent results, including those in environmental or genetic background or those in the clinical set. Our sample included only white patients with diabetes and established coronary artery disease recruited in a very small and homogeneous region of Central-Southern Italy, and HPFS comprises patients with diabetes recruited from all over the U.S., with only 50% of them having baseline CVD. Notably, when HPFS patients with baseline CVD were excluded from the analysis, the association between adiponectin and cardiovascular mortality was no longer significant. This allows for the hypothesis that in the absence of baseline CVD the adiponectin paradox on mortality risk is attenuated, thus making difficult addressing whether causality underlies it. Furthermore, in study by Liu et al. (59), an indispensable prerequisite of Mendelian randomization study (i.e., a strong association between the genetic instrumental variable and the trait of interest) was not satisfied, thus making the risk of false-negative results likely due to poor statistical power. Some further support to a true deleterious role of adiponectin in increasing mortality risk has been provided by a study reporting that a GWAS-derived SNP in CDH13 is associated with both increased HMW adiponectin levels and increased mortality rate (60).

Until larger studies are able to provide more robust data about the possible direct deleterious effect of adiponectin on the risk of death, what could we hypothesize would be the mechanism of such paradox? Recently some deleterious effects of adiponectin on inflammatory processes under specific conditions have been reported. In colonic epithelial cells, adiponectin exerted proinflammatory effects by inducing chemokine production (61); also, adiponectin-deficient mice were protected from chemically induced colitis resembling inflammatory bowel disease, whereas adiponectin infusion restored colon inflammation by inducing local production of proinflammatory cytokines (62). In rheumatoid arthritis, recombinant adiponectin induced synthesis of IL-6 and matrix metalloproteinase inhibitor 1 in human synovial fibroblasts via a p38 mitogen-activated protein kinase pathway (63). Moreover, in cultured chondrocytes from patients with rheumatoid arthritis, adiponectin stimulated the expression of vascular endothelial growth factor, monocyte chemoattractant protein 1, vascular cell adhesion molecule 1, and RANTES (i.e., regulated on activation, normal T cell expressed and secreted), all promoting inflammation (63). Finally, in patients with Crohn disease, adiponectin production was enhanced in hypertrophied mesenteric adipose

---

**The adiponectin paradox**

![Diagram of the adiponectin paradox]

**Figure 1**—The adiponectin paradox. Quite unexpectedly, given its salutary effects on glucose metabolism, inflammation, and several atherosclerotic processes reported by basic science studies, adiponectin seems to be a mere marker of reduced insulin resistance and type 2 diabetes, with no pathogenic role on these metabolic abnormalities (as stressed by the dashed arrow). Even more unexpected are reports showing that adiponectin exerts a neutral effect on nonfatal cardiovascular events and, paradoxically, a deleterious role on both all-cause and cardiovascular mortality.
tissue as compared with control uninflamed tissue (64). Altogether, these data indicate that under some chronic inflammatory conditions, adiponectin, rather than being an anti-inflammatory factor, exacerbates inflammation in several tissues and cell types. Whether such unexpected deleterious roles of adiponectin on inflammation are also operating during low-grade chronic inflammation characterizing CVD and, in general, many frail individuals at high mortality risk and whether this may explain the adiponectin paradox on mortality rate is a possibility that deserves specifically designed studies to be properly addressed.

CONCLUSIONS

The paradigm of a favorable role of adiponectin on metabolic, inflammation, and atherosclerosis processes (3) has been mostly obtained by pioneering studies carried out in cellular and animal models (3,13,18–20) in which the main findings were compatible with results from early small studies in humans (21–23,27,28). However, when looking at large epidemiological and genetic studies it becomes evident, though totally unexpected, that high serum adiponectin is likely to be a mere marker of insulin sensitivity and glucose homeostasis (31), to be neutral in terms of cardiovascular risk (39), and to paradoxically predict increased all-cause and cardiovascular mortality rate (Tables 1 and 2 and Fig. 1).

Several efforts are definitely needed to better understand the adiponectin paradox on the risk of mortality. Among these is setting up a large collaborative prospective study comprising genetic data to answer the question of whether or not adiponectin does exert a direct deleterious role on the risk of death. The same study will offer the opportunity to deeply investigate the role of NPs (55) and insulin sensitivity as confounders or modulators of the adiponectin paradox. Such a study will also make it possible to investigate whether adding circulating adiponectin levels on top of established risk factors improves our ability to predict the risk of mortality across several clinical conditions.

Both basic science and in vivo physiological studies are also needed to understand whether adiponectin resistance underlies the adiponectin paradox and, if so, the intimate molecular mechanism(s) through which this phenomenon occurs.

Finally, only coordinated investigations in cell cultures, animal models, and human beings will address the existence of and mechanisms of adiponectin proinflammatory effects during chronic low-grade inflammation conditions, including CVD, type 2 diabetes, and frailty in elderly people at high mortality risk, and help further the understanding of whether this unexpected scenario plays a role on the adiponectin paradox.

In conclusion, 30 years after its discovery, adiponectin still remains a very elusive molecule. In fact, several epidemiological data question the anti-inflammatory and cardioprotective effects of adiponectin described in basic studies and disappointingly cast doubts on adiponectin as a promising therapeutic target. When it comes to complexity, it does not make sense to try minimizing it: much has been done on adiponectin, but more has to be done.

Funding. This work was supported by the Italian Ministry of Health grants RC2014, RC2015, RC2016, and RF-2013-02356459 (to C.M.) and the Progetti di Ricerca di Interesse Nazionale (PRIN) 2012 grant (to V.T.) and by the Società Italiana di Diabetologia-Fondazione Diabete Ricerca grant 2013 (to C.M.).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

References

1. Dieleman JL, Baral R, Birger M, et al. US spending on personal health care and public health, 1996–2013. JAMA 2016;316:2627–2646
2. Rao Kondapally Seshasai S, Kaptooge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829–841
3. Scherer PE. The multifaceted roles of adipose tissue-therapeutic targets for diabetes and beyond: the 2015 Banting Lecture. Diabetes 2016;65:1452–1461
4. Wu Y, Li Y, Lange EM, et al. Genome-wide association study for adiponectin levels in Filipino women identifies CDH13 and a novel uncommon haplotype at KNG1-ADIPOQ. Hum Mol Genet 2010;19:4955–4964
5. Dastani Z, Hivert MF, Timpson N, et al.; DIAGRAM+ Consortium; MAGIC Consortium; GLGC Investigators; MuTHER Consortium; DIAGRAM Consortium; GANT Consortium; Global B Pgen Consortium; Procardis Consortium; MAGIC investigators; GLGC Consortium. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet 2012;8:e1002607
6. Qi L, Menzaghi C, Salvemini L, De Bonis C, Trischitta V, Hu FB. Novel locus FER is associated with serum HMW adiponectin levels. Diabetes 2011;60:2197–2201
7. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439–451
8. Kobashi C, Ura kaze M, Kishida M, et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 2005;97:1245–1252
9. Ohashi K, Parker JL, Ouchi N, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010;285:6153–6160
10. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002;106:2767–2770
11. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004;109:2046–2049
12. Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramide activity initiates the pleiotropic actions of adiponectin. Nat Med 2011;17:55–63
13. Wong WT, Tian XY, Xu A, et al. Adiponectin is required for PPARγ-mediated improvement of endothelial function in diabetic mice. Cell Metab 2011;14:104–115
14. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int 2009;76:145–148
15. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057–1063
16. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 2004;101:10308–10313
17. Ivanov D, Philippova M, Antropova J, et al. Expression of cell adhesion molecule T-cadherin in the human vasculature. Histochem Cell Biol 2001;115:231–242
18. Denzel MS, Schma IC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 2010;120:4342–4352
19. Parker-Duffen JL, Nakamura K, Silver M, et al. T-cadherin is essential for adiponectin-mediated revascularization. J Biol Chem 2013;288:24886–24897
20. Fujishima Y, Meada N, Matsuda K, et al. Adiponectin association with T-cadherin protects against neointima proliferation and atherosclerosis. FASEB J 2017;31:1571–1583
21. Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002;51:1884–1888
22. Stefan N, Stumvoll M, Vozarova B, et al. Plasma adiponectin and endogenous glucose production in humans. Diabetes Care 2003;26:3315–3319
23. Krafkoff J, Funahashi T, Stouhouer CD, et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003;26:1745–1751
24. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002;51:2968–2974
25. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360:57–58
26. Semple RK, Soos MA, Luan J, et al. Elevated plasma adiponectin in humans with genetically defective insulin receptors. J Clin Endocrinol Metab 2006;91:3219–3223
27. Basu R, Pajvani UB, Rizza RA, Scherer PE. Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes 2007;56:2174–2177
28. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930–1935
29. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27:1133–1163
30. Gao H, Fall T, van Dam RM, et al. Evidence of a causal relationship between adiponectin levels and insulin sensitivity: a Mendelian randomization study. Diabetes 2013;62:1338–1344
31. Yaghoobkar H, Lamina C, Scott RA, et al.; GENESIS Consortium; RISC Consortium. Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes 2013;62:3599–3598
32. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009;302:179–188
33. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730–1737
34. von Eynatten M, Schneider JG, Humpert PM, et al. Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men. J Am Coll Cardiol 2006;47:2124–2126
35. Sattar N, Wannamethee G, Sasnawar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006;114:623–629
36. Sook Lee E, Park SS, Kim E, et al. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol 2013;42:1029–1039
37. Arregui M, Buisjes B, Fritsche A, et al. Adiponectin and risk of stroke: prospective study and meta-analysis. Stroke 2014;45:10–17
38. Wu Z, Cheng Y, Aung LH, Li B. Association between adiponectin concentrations and cardiovascular disease in diabetic patients: a systematic review and meta-analysis. PLoS One 2013;8:e67845
39. Borges MC, Lawlor DA, de Oliveira C, White J, Horta BL, Barros AJ. Role of adiponectin in coronary heart disease risk: a Mendelian randomization study. Circ Res 2016;119:491–499
40. Flegal KM, Kit BK, Orpiana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013;309:71–82
41. Turer AT, Khera A, Ayers CR, et al. Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia 2011;54:2515–2524
42. Choi SH, Ku EJ, Hong ES, et al. High serum adiponectin concentration and low body mass index are significantly associated with increased all-cause and cardiovascular mortality in an elderly cohort, “adiponectin paradox”: the Korean Longitudinal Study on Health and Aging (KLoSHA). Int J Cardiol 2015;183:91–97
43. Tsutamoto T, Tanaka T, Sakai H, et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007;28:1723–1730
44. Poehls J, Wassel CL, Harris TB, et al.; Health ABC Study. Association of adiponectin with mortality in older adults: the Health, Aging, and Body Composition Study. Diabetologia 2009;52:591–595
45. Alam A, Molnar MZ, Czira ME, et al. Serum adiponectin levels and mortality after kidney transplantation. Clin J Am Soc Nephrol 2013;8:460–467
46. Beaty AL, Zhang MH, Ku IA, Na B, Schiller NB, Whooley MA. Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study. Atherosclerosis 2012;220:587–592
47. Rheem CM, Nguyen DV, Moradi H, et al. Association of adiponectin with body composition and mortality in hemodialysis patients. Am J Kid Dis 2015;66:313–321
48. Bergmark BA, Cannon CP, White WB, et al. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. Diabetes Obes Metab 2017;19:962–969
49. Ortega Moreno L, Lamacchia O, Salvenini L, et al. The paradoxical association of adiponectin with mortality rate in patients with type 2 diabetes: evidence of synergism with kidney function. Atherosclerosis 2016;245:222–227
50. Menzagli C, Xu M, Salvenini L, et al. Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism. Cardiovasc Diabetol 2014;13:130
51. Kollents B, Fiser D, Heid IM, Ritz E, Kronenberg F; MMKD Study Group. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int 2007;71:1279–1286
52. Persson J, Strawbridge RJ, McLeod D, et al.; IMPROVE Study Group. Sex-specific effects of adiponectin on carotid intima-media thickness and incident cardiovascular disease. J Am Heart Assoc 2015;4:e001853
53. Wang Y, Ma XL, Lau WB. Cardiovascular adiponectin resistance: the critical role of adiponectin receptor modification. Trends Endocrinol Metab 2017;28:519–530
54. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655–663
55. Tsukamoto O, Fujita M, Kato M, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009;53:2070–2077
56. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet 2017;389:1238–1252
57. Menon V, Li L, Wang X, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2599–2606
58. Ortega Moreno L, Copetti M, Fontana A, et al. Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes. Cardiovasc Diabetol 2016;15:17
59. Liu G, Ding M, Chiue SE, et al. Plasma levels of fatty acid-binding protein 4, retinol-binding protein 4, high-molecular-weight adiponectin, and cardiovascular mortality among men with type 2 diabetes: a 22-year prospective study. Arterioscler Thromb Vasc Biol 2016;36:2259–2267
60. Uetani E, Tabara Y, Kawamoto R, et al. CDH13 genotype-dependent association of high-molecular weight adiponectin with all-cause mortality: the J-SHIPP study. Diabetes Care 2014;37:396–401
61. Ogumwobi OO, Beales IL. Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept 2006;134:105–113
62. Fayad R, Pini M, Sennello JA, et al. Adiponectin deficiency protects mice from chemically induced colonic inflammation. Gastroenterology 2007;132:601–614
63. Liu D, Luo S, Li Z. Multifaceted roles of adiponectin in rheumatoid arthritis. Int Immunopharmacol 2015;28:1084–1090
64. Yamamoto K, Kiyohara C, Murayama Y, et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn’s disease. Gut 2005;54:789–796
65. Elshattou SP, Tsiboulos DI, Tsikou AG, Gratias YE, Pefanis AV, Mountokalakis TD. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 2005;36:1915–1919
66. Kistop C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756–1762
67. Pitz S, Mangge H, Wellnitz B, et al. Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 2006;91:4277–4286
68. Cavusoglu E, Ruwende C, Chopra V, et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 2006;27:2300–2309
69. George J, Patil S, Wexler D, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006;92:1420–1424
70. Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007;167:1510–1517
71. Laughlin GA, Barnett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007;165:164–174
72. Dekker JM, Funahashi T, Njipels G, et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008;93:1489–1496
73. Jorsal A, Tarnow L, Frystyk J, et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 2008;74:649–654
74. Rao M, Li L, Tighiouart H, et al.; HEMO Study Group. Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant 2008;23:2619–2626
75. Ohashi N, Kato A, Misaki T, et al. Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Intern Med 2008;47:485–491
76. Lee SH, Ha JW, Kim JS, et al. Plasma adiponectin and resistin levels as predictors of mortality in patients with acute myocardial infarction: data from Infarction Prognosis Study Registry. Coron Artery Dis 2009;20:33–39
77. Dieplinger B, Haltmayer M, Poelz W, Mueller T. Value of adiponectin as inflammatory markers and relation to survival in the oldest old: the Cardiovascular Health Study All Stars study. J Gerontol A Biol Sci Med Sci 2011;66:1090–1097
78. Drechsler C, Krane V, Winkler K, Dekker FW, Wanner C. Changes in adiponectin levels to number of traditional atherosclerotic risk factors and all-cause mortality and major adverse cardiovascular events (from the Copenhagen City Heart Study). Am J Cardiol 2013;111:1139–1145
79. Hascoet S, Elbaz M, Bongard V, et al. Adiponectin and long-term mortality in coronary artery disease patients and controls. Arterioscler Thromb Vasc Biol 2013;33:67–69
80. Spoto B, Mattace-Raso F, Sibbards E, et al. Resistin and all-cause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients. Nephrol Dial Transplant 2013;28(Suppl. 4):iv181–iv187
81. Szabó T, Scharbakov S, Sandek A, et al. Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr Metab Cardiovasc Dis 2014;24:50–56
82. Chong QD, Mehta RS, Song M, et al. Prediagnostic plasma adiponectin and survival among patients with colorectal cancer. Cancer Prev Res (Phila) 2015;8:1138–1145
83. Tung CW, Hsu YC, Shih YH, Lin CL. Association of adiponectin with high-sensitivity C-reactive protein and clinical outcomes in peritoneal dialysis patients: a 3.5-year follow-up study. PiLSnO One 2015;10:e0141058
84. Delgado GE, Siekmeyer R, Marz W, Kleber ME. Adiponectin and mortality in smokers and non-smokers of the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Adv Exp Med Biol 2016;934:1–8
104. Witberg G, Ayers CR, Turer AT, et al. Relation of adiponectin to all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (from the Dallas Heart Study). Am J Cardiol 2016;117:574–579

105. Pratesi A, Di Serio C, Orso F, et al. Prognostic value of adiponectin in coronary artery disease: role of diabetes and left ventricular systolic dysfunction. Diabetes Res Clin Pract 2016;118:58–66

106. Zhou Y, Zhang J, Zhang W, Ni Z. Association of adiponectin with peripheral arterial disease and mortality in nondiabetic hemodialysis patients: long-term follow-up data of 7 years. J Res Med Sci 2016;21:50

107. Gulin T, Kruljac I, Kirgin Biloš LS, et al. The role of adipokines as prognostic factors of one-year mortality in hip fracture patients. Osteoporos Int 2017;28:2475–2483

108. Karampela I, Kandri E, Antonakos G, et al. Kinetics of circulating fetuin-A may predict mortality independently from adiponectin, high molecular weight adiponectin and prognostic factors in critically ill patients with sepsis: a prospective study. J Crit Care 2017;41:78–85

109. Ritsinger V, Brismar K, Malmberg K, et al. Elevated levels of adipokines predict outcome after acute myocardial infarction: a long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. Diab Vasc Dis Res 2017;14:77–87

110. Maiolino G, Cesari M, Sticchi D, et al. Plasma adiponectin for prediction of cardiovascular events and mortality in high-risk patients. J Clin Endocrinol Metab 2008;93:3333–3340

111. Gardener H, Goldberg R, Mendez AJ, et al. Adiponectin and risk of vascular events in the Northern Manhattan study. Atherosclerosis 2013;226:483–489